Amgen’s (AMGN) shares fell around 8% in early trading on Wednesday as the biopharmaceutical company reported disappointing results. Revenues fell 4% year-on-year to …
Amgen presented results from the Phase 3 ADVANCE trial of Otezla in patients with plaque psoriasis at the American Academy of Dermatology Virtual …
Amgen’s investigational treatment bemarituzumab has received Breakthrough Therapy Designation from the U.S.
Amgen Inc. has agreed to acquire private biopharmaceutical company Rodeo Therapeutics Corporation for a total consideration of $721 million.
U.S.
Amgen, Inc. (NASDAQ:AMGN) shares are falling nearly 10% in Friday’s trading session, leaving investors scratching their heads after the biotech giant actually reported above consensus third-quarter revenues …
Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc. (NASDAQ:CYTK) after Amgen, Inc.
Morgan Stanley analysts were out today with commentary on healthcare giants Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Amgen, Inc. (NASDAQ:AMGN).
Overhang and political rhetoric have paved a tough road for biotech stocks in the past year. Investor concern has been rampant, but the …
Yesterday, Jennifer asked is Valeant Pharmaceuticals the proverbial canary in the coal mine for the pharma industry? She came to the conclusion that …
